Research Article |
Corresponding author: Azizah Nasution ( azizah@usu.ac.id ) Academic editor: Valentina Petkova
© 2022 Peri, Azizah Nasution, Alwi Thamrin Nasution.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Peri, Nasution A, Nasution AT (2022) The role of pharmacists’ interventions in improving drug-related problems, blood pressure, and quality of life of patients with stage 5 chronic kidney disease. Pharmacia 69(1): 175-180. https://doi.org/10.3897/pharmacia.69.e79781
|
This six-month cohort study analyzed the impact of pharmacy interventions (PI) on drug-related problems (DRPs), blood pressure (BP), and quality of life (QoL) among patients with stage 5 chronic kidney disease (CKD) (n = 83) admitted to Pirngadi Hospital, Medan, Indonesia period February to July 2021. DRPs, BP, and QoL of the patients were analyzed before and after PI. DRPs were analyzed applying PCNE version 9, BP scores were extracted from the patients’ medical records. Their QoL was assessed using a WHOQoL questionnaire. The impacts of PI on the incidence of DRPs, BP, and the patients’ QoL were analyzed applying Wilcoxon Signed Rank and Friedman test in the SPSS program version 23.0. The number of DRPs was significantly reduced from 470 before PI to 162 following PI (p = 0.000). The patients’ QoL improved significantly from 40 ± 9.87 before PI to 69 ± 12. 45 after PI, p = 0.000. PI is crucial to improve the outcomes of CKD patients.
Pharmacy intervention, stage 5 CKD, DRPs, blood pressure, QoL
Chronic kidney disease remains a leading global health problem due to its high morbidity and mortality, high treatment costs, and poor clinical outcomes. About one in ten of the world’s population or 850 million people globally suffer from CKD (WHO/WKD 2020). In Indonesia, the prevalence of CKD was about 3.8%. The Indonesian Renal Registry (2018), 2018 indicates large increase in the number of new and active hemodialysis patients in Indonesia. In 2017, the number of new patients was 30,831 and the active hemodialysis patients reached 77,892, while in 2018 number of new patients increased to 66,433 with 132,142 active hemodialysis patients (
Patients with CKD always suffer from comorbidities and complications including hypertension, diabetes mellitus, kidney stones, infection, anemia, and hyperphosphatemia that can worsen the patients’ QoL if not treated appropriately. These comorbidities and complications require complex management which tend to result in increased costs of illness, DRPs, interference with clinical outcomes, reduce the patients’ QoL, and even death (
Many studies on DRPs and clinical outcomes in the management of CKD have been undertaken in different parts of the world. These include a study conducted in Nigeria which identified 234 DRPs in which inappropriate drug selection and drug interactions were the most frequently occurring problems (
In response to the above problems, the present study was conducted to analyze the impacts of PI on DRPs, BP, and QoL of hemodialysis patients with stage 5 CKD undergoing hemodialysis admitted to Dr. Pirngadi hospital, Medan, Indonesia.
This six-month prospective analytical cohort study was conducted to analyze the impact of PI on DRPs, BP, and QoL of hemodialysis patients with stage 5 CKD (n = 83) admitted to Pirngadi hospital period February to July 2021. DRPs, BP, and QoL of the patients were analyzed before and after PI. Ethical clearance was obtained from the Ethics Committee, Faculty of Medicine, University of Sumatera Utara no. 567/KEP/USU/2021. Inclusion criteria were patients with stage 5 CKD admitted to Pirngadi hospital during the period February to July 2021. The minimum number of stage 5 CKD patients required in this study was 15–30 persons (
Patient characteristics during the study period are shown in Table
Gender | Age | Education | Duration hemodialysis | |||||
---|---|---|---|---|---|---|---|---|
Variable | Number (%) | Variable | Number (%) | Variable | Number (%) | Variable | Number (%) | |
Male | 54 (65.06) | ≤40 | 18 (21.68) | Primary school | 3 (3.61) | <1 | 7 (8.44) | |
Female | 29 (34.94) | 41–50 | 22 (26.50) | Junior high school | 5 (6.04) | 1–5 | 50 (60.24) | |
51–60 | 29 (34.93) | Senior high school | 68 (81.92) | >5 | 26 (31.32) | |||
61–70 | 11 (13.28) | University | 7 (8.43) | |||||
71–80 | 2 (2.41) | |||||||
Over 81 | 1 (1.20) | |||||||
Total | 83 (100.00) | Total | 83 (100.00) | Total | 83 (100.00) | Total | 83 (100.00) | |
Total | 83 (100.00) |
In terms of problems, the incidence of DRPs in the management of patients with stage 5 CKD before and after interventions is shown in Table
Code | Problems | Incidence of DRPs | Wilcoxon test (Asymp.Sig) | ||
---|---|---|---|---|---|
Before PI | After PI | % reduction | |||
P | Overall DRPs | 470 | 162 | 65.53 | |
P.1 | Treatment effectiveness | 385 | 152 | 60.51 | 0.000 |
P1.1 | No drug effect | 42 | 10 | 76.19 | |
P1.2 | Sub-optimal drug effects | 239 | 87 | 63.59 | |
P1.3 | Untreated symptoms/ indications | 104 | 55 | 47.11 | |
P.2 | Safety | 83 | 8 | 90.36 | |
P2.1 | Adverse drug reaction (ADRs) events | 83 | 8 | 90.36 | |
P.3 | Others | 2 | 2 | 0 | |
P3.1 | Problems with cost-effectiveness | 2 | 2 | 0 |
As also listed in Table
The incidence of DRPs before and after intervention by cause is listed in Table
Code | Causes (C) | Number of causes | Wilcoxon test (Asymp.Sig) | ||
---|---|---|---|---|---|
Before PI | After PI | % Of Reduction | |||
C | Overall causes | 470 | 162 | 65.53 | 0.000 |
C.1 | Drug Selection | 280 | 109 | 61.07 | |
C1.4 | Inappropriate combination of drugs, drug and herbal remedies, or drugs and herbal supplements | 173 | 29 | 83.23 | |
C1.5 | Inappropriate duplication of therapeutic group or active ingredient | 1 | 0 | 100 | |
C1.6 | No or incomplete drug treatment despite existing indication | 106 | 80 | 24.52 | |
C.3 | Dose selection | 25 | 1 | 96.00 | |
C3.1 | Too low dose | 19 | 1 | 94.73 | |
C3.2 | Too high dose | 6 | 0 | 100 | |
C.4 | Treatment duration | 1 | 0 | 100 | |
C4.2 | Too long duration | 1 | 0 | 100 | |
C.6 | Process of drug administration | 54 | 2 | 96.29 | |
C6.1 | Inappropriate timing of administration or dosing intervals by a health professional | 17 | 2 | 88.23 | |
C6.2 | Under‐administration of drugs by a health professional | 37 | 0 | 100 | |
C.7 | Patient-related | 21 | 3 | 85.71 | |
C7.1 | Patient intentionally uses/takes less drug than prescribed or does not take the drug at all for whatever reason | 6 | 0 | 100 | |
C7.7 | Inappropriate timing/ dosing interval | 1 | 0 | 100 | |
C7.8 | Patient uses drug incorrectly | 14 | 3 | 78.57 | |
C.9 | Others | 90 | 47 | 47.78 | |
C9.2 | Other causes | 90 | 47 | 47.78 |
The level of intervention provided by the pharmacist and its status are listed in Table
Intervention provided by the pharmacist according to level of intervention.
Intervention | Code | Classification | Number of PI | % |
---|---|---|---|---|
I.1 At prescriber level | I1.3 | Intervention suggested to prescribers | 98 | 20.85 |
I1.4 | Intervention discussed with prescribers | 125 | 26.59 | |
I.2 At patient level | I2.1 | Patient counseling | 155 | 32.97 |
I.3 At drug level | I3.2 | Dosage changed | 40 | 8.51 |
I3.4 | Changed instruction for use | 21 | 4.46 | |
I.4 Other intervention | I4.1 | Other intervention | 31 | 6.62 |
Total | 470 | 100 | ||
Status of PI | Code | Classification | Number PI | % |
1. Accepted | A1.1 | Accepted and completely implemented | 52 | 11.06 |
A1.2 | Accepted and partially implemented | 256 | 54.46 | |
A1.3 | Accepted but not implemented | 155 | 34.48 | |
Total | 470 | 100 |
One of the outcomes measured in this study was BP. Changes in BP of the stage 5 CKD patients undergoing hemodialysis before and after intervention are shown in Table
Evaluation | BP | ||
---|---|---|---|
Mean BP | Wilcoxon test (Asymp. sig) | Friedman test (Asymp. sig.) | |
Before PI | 141 ± 18.48 | 0,517 | 0.069 |
Follow up 1 (1 month after PI) | 141 ± 19.10 | ||
Follow up 1 | 141 ± 19.10 | 0,455 | |
Follow up 2 (2 months after PI) | 144 ± 21.89 | ||
Follow up 2 | 144 ± 21.89 | 0,874 | |
Posttest (3 months after PI) | 143 ± 20.39 | ||
Before PI | 141 ± 18.48 | 0,091 | |
After PI | 143 ± 20.39 |
Association among number of DRPs with BP and QoL of the patients before and after interventions is shown in Table
Association among number of DRPs with BP and QoL of the patients before and after intervention.
Number of DRPs Before PI | Number of patients | Mean BP | Mean QoL | Spearman Rho test | Correction Coefficient (r-value) | p |
---|---|---|---|---|---|---|
Before PI | ||||||
1 | 2 | 146 | 42 | DRPs with BP | r = 0.405 | 0.000 |
2 | 2 | 130 | 48 | |||
3 | 5 | 133 | 43 | |||
4 | 15 | 130 | 42 | |||
5 | 16 | 141 | 44 | |||
6 | 15 | 146 | 39 | |||
7 | 15 | 146 | 36 | DRPs with QoL | r=-0.329 | 0.002 |
8 | 4 | 143 | 39 | |||
9 | 5 | 149 | 40 | |||
12 | 2 | 167 | 28 | |||
13 | 1 | 162 | 28 | |||
After PI | ||||||
1 | 23 | 133 | 67 | DRPs with BP | r = 0.304 | 0.005 |
2 | 26 | 144 | 71 | |||
3 | 22 | 149 | 70 | |||
4 | 4 | 159 | 70 | DRPs with QoL | r = 0.156 | 0.158 |
5 | 1 | 183 | 69 |
There was a significant association between the number of incidences with BP of the patients before PI (r = 0.405), p = 0.000. This result implied that the higher the number of DRPs, the higher the patients’ BP. Consistent result was also found in the patients’ QoL. The higher the number of DRPs experienced by the patients, the lower their QoL (r = –0,329), p = 0.002.
Patient characteristics varied widely in terms of age, education, employment, and the disease duration. These conditions were associated with many complicated factors. A systematic review proved that socio-economic conditions including income or occupational levels, education levels, health insurance, and access to healthcare facilities affect the characteristics of CKD patients as well as the disease morbidity and mortality (
The present study proved that the incidence of DRPs both before and after PI varies from one category to another. The highest incidence in problem category was therapeutic effectiveness before and after PI 385 and 152 cases, respectively. The major incidence in causes category was inappropriate combination of drugs with 173 occurrences and 155 DRPs that required patient counseling.
A similar previous study conducted in several tertiary hospitals in Nigeria identified 234 drug therapy problems (DTPs) in which inappropriate drug selection/dosing problems and drug interactions were the major sources of DTPs (
These studies found a wide range of DRPs experienced by CKD patients across countries due to many complex socio-economic factors, level of education, and medication adherence of the patients in particular countries. A study undertaken in K&D Clinic PGIMS, Rohtak, India proved that CKD patients with a higher education and income had a greater adherence to their medications. On the other hand, patients with lower education levels had lower adherence to their prescribed medications as a result of their limited knowledge about the disease they were suffering and the required treatments (
Chronic high BP in stage 5 CKD patients undergoing haemodialysis must be managed to improve clinical outcomes (
In this study, the QoL of patients with stage 5 CKD must also be considered since they tend to experience decreased physical, mental, and social conditions (WHO, 2016). This present study showed significant improvements in QoL following PI. This finding supported a previous study conducted in the HD centers of three different teaching, government, and private hospitals in South India. It was found that HRQoL scores with regard to “physical functioning, general health, emotional well-being, social functioning, symptom/problem list, and effects of kidney disease” in pharmaceutical care group significantly improved over time compared to those in the usual care group with p < 0.05 in all the three centers, which showed an increase in the QoL of CKD patients undergoing hemodialysis after carrying out pharmaceutical care interventions (
The present study proves that PI plays an important role in reducing DRPs, improving BP, and increasing patients’ QoL. Policymakers should consider this finding to improve management of patients with stage 5 CKD. Sufficient numbers of qualified human resources, especially healthcare providers involved in the management of hemodialysis patients are crucial. These factors should be highlighted and considered by policymakers to improve healthcare.
We would like to thank the Director and Head of the Hemodialysis Installation, Pirngadi Hospital, Medan for the support and facilities provided to conduct this study. We would also like to thank all the nurses for the assistance provided.